Back to Top
Announcements

Aims & Scope


Journal of Ocular Pharmacology and Therapeutics is the only peer-reviewed journal that combines ophthalmology and pharmacology to enable optimal treatment, prevention, and diagnosis of ocular diseases and disorders. It presents the latest in the ophthalmic drug discovery, delivery, and product development, emphasizing biopharmaceutics, pharmacokinetics, pharmacodynamics, and mechanisms of drug action.

Journal of Ocular Pharmacology and Therapeutics coverage includes:

  • Drug discovery and development
  • Mechanisms of drug action
  • Drug delivery, nanomedicine, and nanotechnology
  • Biopharmaceutics, pharmacokinetics, pharmacodynamics, and mathematical modeling
  • Drug transporters and drug metabolism
  • Pre-clinical and early-stage clinical trial results
  • Gene and cell-based therapies
  • Combination products
  • Ocular pharmacotherapy/clinical trials/biomarkers
  • Ocular toxicology and toxicokinetics
  • Dry eye and ocular surface diseases
  • Corneal diseases
  • Glaucoma and optic neuropathies
  • Retinal diseases
  • Lens and cataract
  • Ocular infection and trauma
  • Ocular inflammatory and immune disorders
  • Ocular ischemia and blood flow
  • Ocular metabolic disorders
  • Ocular pain
  • Oculomotor complications
  • Proliferative disorders of the eye
  • Therapeutics for myopia and refractive errors
  • Therapeutics for strabismus, ambylopia, and visual processing
  • Eyes on New Product Development — written by Gary D. Novack, PhD, featuring the latest updates on drug and device pipeline developments as well as policy/regulatory changes by the FDA

Journal of Ocular Pharmacology and Therapeutics is under the editorial leadership of Uday B. Kompella, PhD, University of Colorado Anschutz Medical Campus; and his Associate Editors: Linda D. Hazlett, PhD, Wayne State University School of Medicine, Ocular Surface Pharmacology; Michael Niesman, PhD, MingSight Pharmaceuticals, Retinal Pharmacology; Naj A. Sharif, PhD, FARVO, Santen Incorporated, Pre-clinical Ocular Pharmacology; Carol B. Toris, PhD, University of Nebraska Medical Center, Aqueous Humor Dynamics; and an editorial board of leading experts. View the entire editorial board.

Audience: Academic, industry, and government scientists, ophthalmologists, optometrists, clinical and research trainees, and many others

Indexing/Abstracting:

  • PubMed/MEDLINE
  • PubMed Central
  • Current Contents®/Life Sciences
  • Biological Abstracts
  • BIOSIS Previews
  • Journal Citation Reports/Science Edition
  • Prous Science Integrity®
  • Derwent Drug File
  • EMBASE/Excerpta Medica
  • Scopus
  • Chemical Abstracts
  • ProQuest databases
  • CAB Abstracts
  • Global Health
  • Derwent Publications Abstracts
  • BenchSci
The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.